CLARUS THERAPEUTICS HOLDINGS (CRXT)

US18271L1070 - Common Stock

0.099  -0.06 (-36.94%)

After market: 0.101 +0 (+2.02%)

Fundamental Rating

2

Overall CRXT gets a fundamental rating of 2 out of 10. We evaluated CRXT against 198 industry peers in the Pharmaceuticals industry. The financial health of CRXT is average, but there are quite some concerns on its profitability. While showing a medium growth rate, CRXT is valued expensive at the moment.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CRXT has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -66.68%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM -235.99%
PM (TTM) -193%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

CRXT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CRXT remains at a similar level compared to 1 year ago.
Compared to 1 year ago, CRXT has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -11.36, we must say that CRXT is in the distress zone and has some risk of bankruptcy.
There is no outstanding debt for CRXT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.36
ROIC/WACCN/A
WACC6.15%

2.3 Liquidity

CRXT has a Current Ratio of 0.79. This is a bad value and indicates that CRXT is not financially healthy enough and could expect problems in meeting its short term obligations.
CRXT has a Quick Ratio of 0.79. This is a bad value and indicates that CRXT is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.79
Quick Ratio 0.52

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.66% over the past year.
CRXT shows a strong growth in Revenue. In the last year, the Revenue has grown by 39.87%.
EPS 1Y (TTM)43.66%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q84.34%
Revenue 1Y (TTM)39.87%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q-20.73%

3.2 Future

The Earnings Per Share is expected to grow by 14.39% on average over the next years. This is quite good.
CRXT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 57.00% yearly.
EPS Next Y87.39%
EPS Next 2Y39.54%
EPS Next 3Y25.66%
EPS Next 5Y14.39%
Revenue Next Year35.11%
Revenue Next 2Y52.3%
Revenue Next 3Y53.57%
Revenue Next 5Y57%

3.3 Evolution

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRXT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRXT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as CRXT's earnings are expected to grow with 25.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.54%
EPS Next 3Y25.66%

More info and screens

0

5. Dividend

5.1 Amount

CRXT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLARUS THERAPEUTICS HOLDINGS

NASDAQ:CRXT (8/30/2022, 7:05:42 PM)

After market: 0.101 +0 (+2.02%)

0.099

-0.06 (-36.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.15M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -66.68%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM -235.99%
PM (TTM) -193%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.79
Quick Ratio 0.52
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)43.66%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y87.39%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)39.87%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y